Skip to content

Pregabalin, Celecoxib, Total Knee Arthroplasty and Intrathecal Morphine

Comparison of Analgesic Efficacy Among Pregabalin, Celecoxib, Pregabalin With Celecoxib and Placebo After Total Knee Arthroplasty Under Intrathecal Morphine

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01344213
Acronym
PCTKA
Enrollment
100
Registered
2011-04-29
Start date
2008-07-31
Completion date
2010-10-31
Last updated
2011-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain Management, Total Knee Arthroplasty

Keywords

Pregabalin, Celecoxib, Intrathecal morphine, Total knee arthroplasty

Brief summary

To evaluate whether pregabalin and/or celecoxib could improve analgesic efficacy of intrathecal morphine for patients after total knee arthroplasty.

Detailed description

A single-dose spinal anesthesia combining with morphine for total knee arthroplasty (TKA) is a simple, economical anesthetic technique commonly used in our hospital. Still some patients could not get effective postoperative pain control. Pregabalin, an anticonvulsant, has been shown to reduce acute pain after molar extraction, laparoscopic cholecystectomy, and reduce postoperative morphine requirement after total hip arthroplasty, and celecoxib, a selective cyclo-oxygenase (COX) - 2 inhibitor, with perioperative prescription is successfully reduces pain score and opioid consumption after TKA under spinal anesthesia alone. However, no clinical study has yet investigated whether preoperative single-dose of pregabalin, celecoxib or in combination compared to placebo can improve analgesic efficacy of intrathecal morphine after TKA. The primary objective of this study was to evaluate whether these medications could reduce pain scores at rest / when movement and morphine requirement after TKA under spinal anesthesia with intrathecal morphine. Secondary outcome assessed include adverse effects, anxiety score and patients' satisfaction score.

Interventions

DRUGPregabalin

Oral single-dose of pregabalin (150 mg) and placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.

DRUGCelecoxib

Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.

DRUGPregabalin with celecoxib

Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.

DRUGPlacebo

Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg

Sponsors

Bhumibol Adulyadej Hospital
CollaboratorOTHER
King Chulalongkorn Memorial Hospital
CollaboratorOTHER
Chulalongkorn University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients between 50-75 years of age * Patients with an American Society of Anesthesiologists physical status of I to III * Patients scheduled for primary TKA with a diagnosis of osteoarthritis under spinal anesthesia

Exclusion criteria

. * Patients had a known allergy to any of the medications being used * a history of drug or alcohol abuse * a history of taking chronic pain medications (ie, show-release preparations of opioids, given that morphine consumption was the primary outcome) * a history of taking pregabalin or gabapentin / non-steroidal anti-inflammatory drugs / COX-2 inhibitors * a psychiatric disorder * a history of impaired renal function (Cr \> 1.5 mg/dl), peptic ulcer, asthma, thrombotic cerebrocardiovascular diseases, uncontrolled hypertension * a history of contraindication for spinal anesthesia * a history of bleeding tendency * pregnancy * unable or unwilling to use patient - controlled analgesic (PCA)

Design outcomes

Primary

MeasureTime frameDescription
24-hour cumulative morphine consumptionParticipants will be followed for the duration of hospital stay, an expected average of 2 weeks* The time to first morphine requirement will be recorded * The cumulative morphine consumption will be recorded at the end of surgery and 2-h, 6-h, 10-h, 24-h, and 48-h postoperatively * Visual analog scale (VAS) pain scores at rest will be assessed at the night before surgical date, before starting anesthesia, at the end of surgery, and 2-h, 6-h, 10-h, 24-h and 48-h postoperatively * Visual analog scale (VAS) pain scores when on movement will be assessed at the end of surgery, and 2-h, 6-h, 10-h, 24-h and 48-h postoperatively

Secondary

MeasureTime frameDescription
Anxiety scores (VAS), patients' satisfactionParticipants will be followed for the duration of hospital stay, an expected average of 2 weeks* Anxiety scores will be assessed at the night before surgical date, before starting anesthesia, at the end of surgery, and 2-h, 6-h, 10-h, 24-h and 48-h postoperatively; * 24-h and 48-h patients' satisfaction (0-10,0=dissatisfied and 10= very satisfied)

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026